Revista Romana de Boli Infectioase | Volumul XVII, Nr. 1, An 2014
ISSN 1454-3389  |  e-ISSN 2069-6051
ISSN-L 1454-3389

Indexed in / abstracted by

Thomson Reuters Embase
Scopus Cross-ref
Index Copernicus
Ulrichs Ebsco Host
Medline - Ebsco PubMed


Publicarea de articole stiintifice

Stimati cititori, va reamintim ca autorii primi ai articolelor stiintifice pot acumula 80 de credite EMC in urma publicarii. Daca un articol are mai multi autori, cele 80 de credite [...]

Society’s Prize for authors

Starting with 2016, The Romanian National Society of Infectious Diseases offers Society’s Prize – for the authors who published the best scientific articles [...]

Plagiatul – in actualitate

Tema plagiatului este tot mai mult discutata in ultima vreme. Aparitia unor programe performante de cautare si identificare a similitudinilor intre texte [...]


, and


Despite the innovations in the past years in the field of chronic hepatitis C treatment, Hepatitis C virus (HCV) infection remains an important global burden with elevated healthcare costs and high morbidity and mortality due to its complications – liver cirrhosis and hepatocellular carcinoma. The interrelation between HCV and host’s lipid metabolism is widely accepted, as it has been proved in many clinical and research studies. HCV infection is associated with different types of metabolic disorders such as liver steatosis and insulin-resistance. On the other side these metabolic disturbances induce an accelerated progression of liver disease. HCV interacts with host lipids in every step of viral life cycle: viral transport in the blood stream, cell entry, replication, assembly and transport to the extra-cellular space. This review focuses on the complex link between HCV and host lipids, emphasizing the clinical implications of these interactions. Although the pathogenic mechanisms of HCV infection are incompletely understood, recent literature data elucidates some important aspects which opened a road to innovating therapeutic approaches such as host targeting agents, with a pan-genotypic antiviral effect and high genetic barrier. Targeting parts of the pathogenic pathways of HCV infection represents a new kind of therapeutic approach, hopefully with higher treatment success rates and lowering morbidity and mortality related to this infection.

Keywords: chronic hepatitis C, lipid metabolism, pathogenesis

Full text | PDF

Leave a Reply